AH-008 Achieves Key Clinical Milestone with Successful First Subject First Dose (FSFD) in Phase I Study for Prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
· cision pr newswire
AI Briefing
- • AnHorn Medicines announces successful completion of Phase I trial for AH-008, a neuroprotective candidate for CIPN.
- • AH-008 aims to prevent chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients.
- • The first subject first dose was successfully completed in the Phase I study.
Context
AnHorn Medicines announced the successful completion of the first subject first dose in the Phase I clinical trial of AH-008. The trial is for the prevention of chemotherapy-induced peripheral neuropathy. AH-008 is a first-in-class neuroprotective candidate.
The achievement of this key clinical milestone is significant for the development of AH-008. The Phase I clinical trial is a step towards preventing chemotherapy-induced peripheral neuropathy, a condition associated with chemotherapy.
Advertisement